Indications for the drug Mexidol® solution for injection 5%
acute cerebrovascular accidents;
encephalopathy;
vegetative-vascular dystonia;
atherosclerotic disorders of brain function;
neurotic and neurosis-like disorders with anxiety;
relief of withdrawal syndrome in alcoholism with the presence in the clinical picture of neurosis-like and vegetative-vascular disorders, as well as acute intoxication with neuroleptics;
in the complex treatment of acute purulent-inflammatory processes of the abdominal cavity (acute destructive pancreatitis, peritonitis).
Directions for use and doses
IM or IV (stream or drip). For intravenous administration, water for injection is used as a solvent. Mexidol is administered in a stream over 5–7 minutes, and dropwise at a rate of 60 drops per minute. Doses are selected individually.
Begin treatment with a dose of 0.05–0.1 g 1–3 times a day, gradually increasing the dose until a therapeutic effect is obtained. The duration of treatment and the choice of individual dose depend on the severity of the patient’s condition and the effectiveness of treatment. The maximum daily dose should not exceed 0.8 g.
For the treatment of atherosclerotic dementia in elderly patients, Mexidol is prescribed intramuscularly at a dose of 0.1–0.3 g/day.
In case of acute intoxication with neuroleptics, the drug is administered into a vein at a dose of 0.5–0.3 g/day.
In the complex treatment of acute purulent-inflammatory processes of the abdominal cavity (acute destructive pancreatitis, peritonitis), Mexidol is prescribed in a single dose of 200 mg 3 times a day. In case of severe disease, the drug is diluted in 200 ml of physiological 0.9% sodium chloride solution and administered at a rate of 40–60 drops per minute. For milder cases of the disease, Mexidol is administered intramuscularly. The course of treatment is 3–10 days.
Mexidol amp 50mg/ml 2ml N10 (Vectorfarm)
IM or IV (stream or drip).
When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.
Mexidol® is injected slowly over 5-7 minutes in a stream, and dropwise at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.
For acute cerebrovascular accidents
Mexidol® is used in the first 10-14 days - 200-500 mg IV drip 2-4 times a day, then 200-250 mg IM 2-3 times a day for 2 weeks.
For traumatic brain injury and consequences of traumatic brain injury
Mexidol® is used for 10-15 days intravenously at a dose of 200-500 mg 2-4 times a day.
For dyscirculatory encephalopathy in the decompensation phase
Mexidol® should be prescribed intravenously in a stream or drip at a dose of 200-500 mg 1
-
2 times a day for 14 days. Then IM 100-250 mg/day. over the next 2 weeks.
For course prophylaxis of dyscirculatory encephalopathy
the drug is administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days.
For mild cognitive impairment in elderly patients and anxiety disorders
the drug is used intramuscularly at a daily dose of 100-300 mg/day for 14-30 days.
In acute myocardial infarction as part of complex therapy
Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic agents according to indications.
In the first 5 days, to achieve maximum effect, it is advisable to administer the drug intravenously; in the next 9 days, Mexidol® can be administered intramuscularly. Intravenous administration of the drug is carried out by drip infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100-150 ml for 30-90 minutes. If necessary, a slow jet injection of the drug, lasting at least 5 minutes, is possible.
The drug is administered (intravenous or intramuscular) 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg/kg body weight per day, a single dose is 2-3 mg/kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.
For open-angle glaucoma of various stages as part of complex therapy
Mexidol® is administered intramuscularly at 100-300 mg/day, 1-3 times a day for 14 days.
For alcohol withdrawal syndrome
Mexidol® is administered in a dose of 200-500 mg intravenously or intramuscularly 2-3 times a day for 5-7 days.
In case of acute intoxication with antipsychotic drugs
the drug is administered intravenously at a dose of 200-500 mg/day for 7-14 days.
In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis)
the drug is prescribed on the first day both in the preoperative and postoperative periods. The administered doses depend on the form and severity of the disease, the prevalence of the process, and variants of the clinical course. The drug should be discontinued gradually only after a stable positive clinical and laboratory effect.
For acute edematous (interstitial) pancreatitis
Mexidol® is prescribed 200-500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly.
Mild severity of necrotizing
pancreatitis
- 100-200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly.
Moderate severity
- 200 mg 3 times a day, intravenously (in 0.9% sodium chloride solution).
Severe course
— in a pulse dosage of 800 mg on the first day, with a two-time administration regimen; then 200-500 mg 2 times a day with a gradual reduction in the daily dose.
Extremely severe course
- at an initial dosage of 800 mg/day until the manifestations of pancreatogenic shock are persistently relieved, upon stabilization of the condition, 300-500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.
Mexidol solution d/iv and intramuscular injection 5% ampoule 2ml No. 10
Pharmacodynamics
It has antihypoxic, membrane protective, nootropic, anticonvulsant and anxiolytic effects, increases the body's resistance to stress.
The drug increases the body's resistance to the effects of major damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accidents, intoxication with alcohol and antipsychotic drugs /neuroleptics/). Mexidol® improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the level of total cholesterol and LDL.
Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
The mechanism of action of the drug Mexidol® is due to its antihypoxic, antioxidant and membrane protective effects. The drug inhibits the processes of lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Mexidol® modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, neurotransmitter transport and improve synaptic transmission. Mexidol® increases dopamine levels in the brain. Causes an increase in the compensatory activity of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, with an increase in the content of ATP, creatine phosphate and activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.
Mexidol® normalizes metabolic processes in the ischemic myocardium, reduces the necrosis zone, restores and improves the electrical activity and contractility of the myocardium, and also increases coronary blood flow in the ischemic zone, reduces the consequences of reperfusion syndrome in acute coronary insufficiency. Increases the antianginal activity of nitro drugs. Mexidol® promotes the preservation of retinal ganglion cells and optic nerve fibers during progressive neuropathy, the causes of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increasing visual acuity.
